290 related articles for article (PubMed ID: 27776715)
1. Characterization of Lipoprotein-associated Phospholipase A2 in Serum in Patients With Stage 3-5 Chronic Kidney Disease.
Wang Y; Li SS; Na SP; Yu CY; Ji Y; Zhao SL; Xie RJ; Bao YS
Am J Med Sci; 2016 Oct; 352(4):348-353. PubMed ID: 27776715
[TBL] [Abstract][Full Text] [Related]
2. Interpretation of lipoprotein-associated phospholipase A2 levels is influenced by cardiac disease, comorbidities, extension of atherosclerosis and treatments.
Charniot JC; Khani-Bittar R; Albertini JP; Giral P; Cherfils C; Cosson C; Guillerm E; Leprince P; Gandjbakhch I; Bonnefont-Rousselot D
Int J Cardiol; 2013 Sep; 168(1):132-8. PubMed ID: 23103135
[TBL] [Abstract][Full Text] [Related]
3. Lipoprotein-associated phospholipase A2 (Lp-PLA2) and tumor necrosis factor-alpha (TNF-α) and their relation to premature atherosclerosis in β-thalassemia children.
Ragab SM; Safan MA; Obeid OM; Sherief AS
Hematology; 2015 May; 20(4):228-38. PubMed ID: 25056687
[TBL] [Abstract][Full Text] [Related]
4. Patients with early rheumatoid arthritis exhibit elevated autoantibody titers against mildly oxidized low-density lipoprotein and exhibit decreased activity of the lipoprotein-associated phospholipase A2.
Lourida ES; Georgiadis AN; Papavasiliou EC; Papathanasiou AI; Drosos AA; Tselepis AD
Arthritis Res Ther; 2007; 9(1):R19. PubMed ID: 17326817
[TBL] [Abstract][Full Text] [Related]
5. Differential Expression of Lipoprotein-Associated Phospholipase A2 in Monocyte Subsets: Impact of Uremia and Atherosclerosis.
Ulrich C; Trojanowicz B; Fiedler R; Kohler F; Wolf AF; Seibert E; Girndt M
Nephron; 2017; 135(3):231-241. PubMed ID: 27992874
[TBL] [Abstract][Full Text] [Related]
6. The role of lipoprotein-associated phospholipase A2 in atherosclerosis may depend on its lipoprotein carrier in plasma.
Tellis CC; Tselepis AD
Biochim Biophys Acta; 2009 May; 1791(5):327-38. PubMed ID: 19272461
[TBL] [Abstract][Full Text] [Related]
7. Lipoprotein profile, lipoprotein-associated phospholipase A2 and cardiovascular risk in hemodialysis patients.
Rolla R; De Mauri A; Valsesia A; Vidali M; Chiarinotti D; Bellomo G
J Nephrol; 2015 Dec; 28(6):749-55. PubMed ID: 25971848
[TBL] [Abstract][Full Text] [Related]
8. Role of lipoprotein-associated phospholipase A2 activity for the prediction of silent brain infarcts in women.
Riba-Llena I; Penalba A; Pelegrí D; Vilar A; Jarca CI; Filomena J; Montaner J; Delgado P;
Atherosclerosis; 2014 Dec; 237(2):811-5. PubMed ID: 25463126
[TBL] [Abstract][Full Text] [Related]
9. Lipoprotein-associated phospholipase A2 is a risk factor for diabetic kidney disease.
Hu Y; Li TT; Zhou W; Lu TT; Li FF; Ding B; Liu BL; Xie XJ; Ma JH
Diabetes Res Clin Pract; 2019 Apr; 150():194-201. PubMed ID: 30904742
[TBL] [Abstract][Full Text] [Related]
10. The Relationship Between Lipoprotein-Associated Phospholipase A(2), Cholesteryl Ester Transfer Protein and Lipid Profile and Risk of Atherosclerosis in Women with Iron Deficiency Anaemia.
Yang S; Chen XY; Xu XP
Clin Lab; 2015; 61(10):1463-9. PubMed ID: 26642708
[TBL] [Abstract][Full Text] [Related]
11. [Lipoprotein-associated phospholipase A2 serum levels in patients from different categories of cardiovascular risk].
Nozadze DN; Sergienko IV; Balakhonova TV; Semenova AE; Vlasik TN; Kukharchuk VV
Kardiologiia; 2014; 54(3):57-63. PubMed ID: 25102750
[TBL] [Abstract][Full Text] [Related]
12. Lipoprotein-associated phospholipase A2 is elevated in patients with severe aortic valve stenosis without clinically overt atherosclerosis.
Kolasa-Trela R; Fil K; Bazanek M; Grudzień G; Sobczyk D; Sadowski J; Undas A
Clin Chem Lab Med; 2012 Oct; 50(10):1825-31. PubMed ID: 23089713
[TBL] [Abstract][Full Text] [Related]
13. Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) in acute coronary syndrome: relationship with low-density lipoprotein cholesterol.
Jabor B; Choi H; Ruel I; Hafiane A; Mourad W; Genest J
Can J Cardiol; 2013 Dec; 29(12):1679-86. PubMed ID: 24267807
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of Lipoprotein-Associated Phospholipase A2 as a Prognostic Biomarker in Chronic Kidney Disease.
Qu H; Zhang G; Pan J; Huang Y; Lv W
Clin Lab; 2021 Aug; 67(8):. PubMed ID: 34383418
[TBL] [Abstract][Full Text] [Related]
15. Darapladib, a Lipoprotein-Associated Phospholipase A2 Inhibitor, Reduces Rho Kinase Activity in Atherosclerosis.
Zhang J; Xu DL; Liu XB; Bi SJ; Zhao T; Sui SJ; Ji XP; Lu QH
Yonsei Med J; 2016 Mar; 57(2):321-7. PubMed ID: 26847282
[TBL] [Abstract][Full Text] [Related]
16. Lipoprotein-associated phospholipase A
Garg PK; Jorgensen NW; McClelland RL; Jenny NS; Criqui MH; Allison MA; Greenland P; Rosenson RS; Siscovick DS; Cushman M
Vasc Med; 2017 Feb; 22(1):5-12. PubMed ID: 28215109
[TBL] [Abstract][Full Text] [Related]
17. Elevated circulating levels of lipoprotein-associated phospholipase A2 in obese children.
Sakka S; Siahanidou T; Voyatzis C; Pervanidou P; Kaminioti C; Lazopoulou N; Kanaka-Gantenbein C; Chrousos GP; Papassotiriou I
Clin Chem Lab Med; 2015 Jun; 53(7):1119-25. PubMed ID: 25581763
[TBL] [Abstract][Full Text] [Related]
18. Association of lipoprotein-associated phospholipase A2 mass with asymptomatic cerebral artery stenosis.
Wang Y; Zhou B; Zhou P; Yao Y; Cui Q; Liu Y; Yang J; Wu S; Zhao X; Zhou Y
J Cell Mol Med; 2018 Apr; 22(4):2329-2336. PubMed ID: 29424477
[TBL] [Abstract][Full Text] [Related]
19. Advantages of the lipoprotein-associated phospholipase A2 activity assay.
Donato LJ; Meeusen JW; Callanan H; Saenger AK; Jaffe AS
Clin Biochem; 2016 Jan; 49(1-2):172-5. PubMed ID: 26365697
[TBL] [Abstract][Full Text] [Related]
20. Biological variability of lipoprotein-associated phospholipase A
Donato LJ; Meeusen JW; Jenkins SM; Hartman SJ; Saenger AK; Baumann NA; Block DR; Jaffe AS
Clin Biochem; 2017 Apr; 50(6):347-349. PubMed ID: 27894953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
